influenza a and b

Oseltamivir phosphate (GS 4104) is a neuraminidase (NA) inhibitor with oral activity. Oseltamivir phosphate has antiviral activity and is effective against a wide range of influenza viruses, inhibiting mature influenza viruses from breaking away from host cells.

2′-Deoxy-2′-fluoroguanosine is a nucleoside analog that potently inhibits influenza virus A and B strains(EC90 <0.35 μM). 2'-Deoxy-2'-fluoroguanosine is an inhibitor of influenza virus replication in the upper respiratory tract, improving fever and nasal inflammation.

BMY-27709 is an influenza virus growth inhibitor with an IC50 value of 3-8 μM against A WSN 33 virus growth and demonstrates inhibitory activity against certain subtypes of influenza viruses. BMY-27709 acts early in H1 and H2 virus infections by inhibiting hemagglutinin proteins but has no effect on H3 subtype viruses and influenza B Lee 40 viruses.

Peramivir Trihydrate (RWJ-270201) is a neuraminidase inhibitor (IC50: 0.09 nM) which prevents normal processing of virus particles such that virus particles are not released from infected cells. Peramivir Trihydrate is a cyclopentane derivative with activity against influenza A and B viruses.

Baloxavir marboxil (S-033188) is a novel cap-dependent endonuclease inhibitor designed for the treatment of influenza A and B virus infections.

Amitivir (LY 217896) is an inosine monophosphate dehydrogenase inhibitor. Amitivir inhibits the replication of dividing MDCK cells. Amitivir was associated with asymptomatic rises in serum uric acid levels and was ineffective in modifying the virologic or clinical course of experimental influenza A (H1N1) virus infection.

RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.

DPQ is an antiviral compound. DPQ has also been shown to bind to a widened RNA major groove at the internal loop. DPQ acts against the H1N1 and H3N2 strains of influenza A as well as influenza B.

ATV03 is an antiviral agent exhibiting potent activity against both type A and type B influenza viruses. It inhibits the type A (H3N2) and type B influenza viruses with EC50 values of 0.78 nM and 2.02 nM, respectively. The mechanism of action of ATV03 involves the inhibition of the polymerase acidic protein (PA) and RNA-dependent RNA polymerase (RdRp), as well as the disruption of nucleoprotein, thereby exerting its antiviral effects against influenza.

AV-5080 is an orally active neuraminidase (neuraminidase) inhibitor that is utilized in the research of both Type A and Type B influenza viruses.

Peramivir (BCX1812) is a highly selective influenza A and B neuraminidase inhibitor with antiviral activity and anti-cytokine effects, which can be used in the study of novel coronavirus and influenza virus infections.

Zanamivir hydrate is neuraminidase inhibitors. It is used worldwide for the treatment and prophylaxis of influenza caused by influenza A and B viruses.

Oseltamivir-acetate, an impurity of Oseltamivir, is a recommended neuraminidase inhibitor for both the treatment and prophylaxis of influenza A and B[1][2].

Zanamivir-13C,15N2is intended for use as an internal standard for the quantification of zanamivir by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.1It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50values ranging from 0.6 to 7.9 nMin vitro. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza. 1.Elliott, M.Zanamivir: From drug design to the clinicPhilos. Trans. R. Soc. Lond. B Biol Sci.356(1416)1885-1893(2001)

Ribavirin-13C5is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin is an antiviral guanosine nucleoside analog.1,2Upon entry into cells, ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg) reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV), hepatitis C virus (HCV), and viral hemorrhagic fevers. 1.Gilbert, B.E., and Knight, V.Biochemistry and clinical applications of ribavirinAntimicrob. Agents Chemother.30(2)201-205(1986) 2.Gordon, C.J., Tchesnokov, E.P., Woolner, E., et al.Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyJ. Biol. Chem.295(20)6785-6797(2020) 3.Kirsi, J.J., North, J.A., McKernan, P.A., et al.Broad-spectrum antiviral activity of 2-β-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agentAntimicrob. Agents Chemother.24(3)353-361(1983) 4.Wang, M., Cao, R., Zhang, L., et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30(3)269-271(2020) 5.Wilson, S.Z., Knight, V., Wyde, P.R., et al.Amantadine and ribavirin aerosol treatment of influenza A and B infection in miceAntimicrob. Agents Chemother.17(4)642-648(1980)

Oseltamivir (GS 4104) is an orally active and highly potent viral neuraminidase (NA) with antiviral activity, inhibits A H3N2, A H1N2, A H1N1 and influenza B viruses, and can be used in studies of influenza and pneumonia.

Cap-dependent endonuclease-IN-26, a potent inhibitor of cap-dependent endonuclease (CEN) with an IC50 of 286 nM, exhibits significant antiviral activity against a broad spectrum of influenza A and B strains [1].

HSP90-IN-14 (compound 4) is an effective Hsp90 inhibitor (Kd=0.26 μM). In MDCK cells, HSP90-IN-14 demonstrated anti-influenza virus activity with EC50 values of 2.6 μM against influenza A H3N2, 3.9 μM against A H1N1, and 17 μM against the B virus.

RdRP-IN-4 (compound 11q) is an arylbenzohydrazide analogue, an orally active inhibitor of influenza A virus RNA-dependent RNA polymerase (RdRp) that directly binds the PB1 subunit of RdRp. RdRP-IN-4 inhibited H1N1 (A PR 8 34) Flu A and Flu B strains (B Lee 1940) in a dose-dependent manner with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 had a significant antiviral effect in infected mice.

Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN), effectively inhibiting influenza viruses with low cytotoxicity, good in vivo pharmacokinetic and pharmacodynamic properties, and good hepatic microsomal stability. It has shown investigational potential against viral infections, including influenza A, B, and C.

Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) that effectively inhibits the replication of orthomyxoviruses, including influenza A, B, and C.

Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN), demonstrating potential for investigating influenza A and B infections.

FA-613 is a pyrimidine synthesis inhibitor which exhibits low micromolar antiviral activity against various influenza A and B virus strains, including the highly pathogenic influenza A strains H5N1 and H7N9, enterovirus A71, respiratory syncytial virus, human rhinovirus A, SARS- and MERS-coronavirus.

Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN), effectively inhibiting viral mRNA synthesis and halting virus proliferation, making it especially promising for research into viral infections, including influenza types A, B, and C.